The Future of ART Regimens for HIV Is in Long-Acting Agents
Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don’t require a daily oral pill and two-drug regimens that could decrease toxicity associated with standard triple-drug regimens. The approval of cabotegravir plus rilpivirine (Cabenuva) in January 2021 was the first to provide both benefits as a monthly ART injection. The approval was expanded to […]
Doublet Shows Activity in Rare, Aggressive Kidney Cancer
There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in patients with hereditary papillary renal cell carcinoma. The combination was approximately half as effective in patients with sporadic papillary renal cell carcinoma. Bevacizumab (Avastin) combined with erlotinib […]